Heparinex, L.L.C. is a biopharmaceutical company focused on the novel recombinant synthesis of compounds for markets including anticoagulation, inflammation, and cancer treatment areas. Leading carbohydrate chemist and glycobiologist Dr. Paul DeAngelis, originally discovered and patented Heparinex’s core technology platforms of proprietary carbohydrate production.
Heparinex was founded upon the discovery of two novel methodologies to produce synthetic heparinoid compounds in a highly controlled manner. Heparin is used as an anticoagulant and antithrombotic agent in a wide variety of medical conditions. Traditional production techniques involve procuring and purifying heparin from sources such as porcine intestine and bovine lung. While the current methods are adequate, they limit the potential applications of heparin due to the inherent variability in the molecular size and weight of the heparin chains. The Heparinex solution circumvents these issues by providing techniques to produce uniform monodisperse heparin chains.
As a postdoctoral researcher (1990-93) in the laboratory of Dr. Paul Weigel at the University of Texas Medical Branch, Galveston, Dr. DeAngelis identified the first hyaluronan synthase to be described from the human bacterial pathogen Group A Streptococcus. Currently, as a Professor at the University of Oklahoma Health Sciences Center in Oklahoma City, he directs a laboratory exploring various aspects of prokaryotic and eukaryotic polysaccharide biosynthesis. Discoveries from 1997 to 2003 include the identification of two more unique hyaluronan synthases and the first chondroitin and heparin synthase.
For more information CLICK HERE.
Glycobiology. 2017 Nov 1;27(11):1062-1074.
Glycobiology. 2017 Nov 1;27(11):1052-1061.
Glycobiology. 2017 Jul 1;27(7):646-656.